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1. Introduction 
Defensins and cathelicidins are the two major endogenous antimicrobial peptide families in 
mammals, which are abundant components of phagocytic leukocytes and are released by 
epithelial cells at mucosal surfaces. Defensins are antimicrobial peptides produced at a 
variety of epithelial surfaces. In the small intestine Paneth cells secrete ǂ-defensins and 
additional antimicrobial peptides at high levels in response to cholinergic stimulation and 
when exposed to bacterial antigens. In the intestinal tract ǂ- and ǃ-defensins contribute to 
host immunity and assist in maintaining the balance between protection from pathogens 
and tolerance to normal flora. However, attenuated expression of these defensins 
compromises host immunity and hence may alter the balance toward inflammation. Altered 
defensins production is suggested to be an integral element in the pathogenesis of ulcerative 
colitis (UC). Recent years, the defensins have attracted great attention because of their roles 
in the organism defense system. This review highlights the current knowledge of defensins, 
distribution, structures, the diverse functions in the immune response and the changes of 
defensins expression in UC and the potential role in the pathogenesis of UC. 
2. Structures of defensins 
Antimicrobial peptides are gene-encoded natural antibiotics produced by virtually every life 
form studied (Boman, 1995; Zasloff, 2002). In mammals, defensins are a major (if not 
predominant) group of antimicrobial peptides. In the 1980s, Lehrer et al. first found a series 
of small molecules cationic peptides with similar structures to rabbit and human neutrophil 
cytoplasmic granules, which were first named “defensins” (Lehrer et al., 1980). A 
fundamental characteristic of defensins peptides is the presence of three intramolecular 
disulfide bonds (Ganz, 2003). The defensins are thus subdivided into three subgroups 
(designated ǂ-, ǃ-, and θ-defensins). The subgroups are based largely on the connectivity of 
three cystine linkages (Table 1), but structural features of the gene and precursor are also 
further distinguishing characteristics. 
The three-dimensional structures of several ǂ- and ǃ-defensins have been determined by 
both nuclear magnetic resonance (NMR) and X-ray crystallography techniques (Hill et al., 
1991; Zhang et al., 1992; Pardi et al., 1992; Skalicky et al., 1994; Zimmermann et al., 1995; 
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Sawai et al., 2001). Although crystal structures of some defensins are made up of dimers or 
multimers, it has not been yet clear whether these multimers are the biologically relevant to 
different forms of defensins. 
 
Defensins Peptide size Cysteine 
Linkages
Size Expression 
Sites 
Expression 
Patterns 
Species 
Distribution 
ǂ-defensins 30~34 aa 1-6, 2-4, 3-
5 
90-105 
aa 
Neutrophils, 
Macrophage, 
Paneth cells, 
Reproductive 
epithelia 
Mostly 
constitutive
Primates 
Rodents 
Rabbits 
ǃ-defensins 36~44 aa 1-5, 2-4, 3-
6 
60-70 
aa 
Mucosal 
epithelia and 
Skin, 
Ruminant, 
Heterophils, 
Epididymis 
Mostly 
inducible 
Primates 
Rodents 
Ruminants 
Birds 
Crustaceans 
θ-defensins 18 aa (two 
connected 
hemi-peptides 
of 9 aa each) 
1-1′, 2-3, 
2′-3′ 
90 aa  Neutrophils Constitutive Non-human 
primates 
Table 1. Comparison of ǂ-defensins, ǃ-defensins and θ-defensins 
The 3D structures of ǂ- and ǃ-defensins contain a canonical triple-stranded antiparallel ǃ-
sheet motif. Solution and crystallographic analyses of ǃ-defensins have revealed that the ǂ- 
and ǃ-defensins folds are similar as the amphipathicity is produced by the distribution of 
polar and hydrophobic side chains on the peptide surfaces. However, both ǃ-defensins 
possess short ǂ-helical segments that ǂ-defensins lack. There is no evident relationship 
between ǃ-sheet content and antimicrobial activity, and knowledge of the general structural 
factors that modulate the antimicrobial spectrum and activity of defensins is for the most 
part lacking. 
The solution structures of closed circular rhesus θ-defensin-1 (RTD-1) and its open chain 
analog (oRTD-1) have been determined by two-dimensional NMR. RTD-1 and oRTD-1 
adopt very similar structures in water, containing an extended ǃ-hairpin, structure with 
turns at one end in oRTD-1 or in both ends in circular RTD-1. The double stranded ǃ-sheet 
region of the two molecules is flexible, and, because the structures and flexibilities of RTD-1 
and oRTD-1 are similar, the reduced antimicrobial activity of oRTD-1 relative to circular 
RTD-1 is attributable to the charged N- and C-termini of the oRTD-1 molecule (Trabi et al., 
2001; Ouellette, 2006). In contrast to many antimicrobial peptides, RTD-1 has no amphiphilic 
character, even though surface models of RTD-1 exhibit a certain clustering of positive 
charges. 
3. Characteristics of defensins distribution 
Defensins are abundant in cells and tissues that are involved in host defense against 
microbial infections. Notably, the specific tissue distribution of defensins diverged rapidly 
during vertebrate evolution (Table 2). To date, 12 different human ǂ-defensins and 48 
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human ǃ-defensins, 22 mouse ǂ-defensins and 26 mouse ǃ-defensins have been identified 
and isolated (http://defensins.bii.a-star.edu.sg). In the alimentary tract of mammals, ǂ-
defensins are highly expressed and largely confined to the small intestine, whereas ǃ-
defensins are found to be inducible expression at sites of infection or inflammation. 
 
Species Neutrophil defensins Paneth cell defensins Epithelial cell defensins 
Human ǂ  ǂ ǂ and ǃ 
Rhesus 
monkey 
ǂ and θ Not determined ǃ 
Mouse none ǂ ǂ and ǃ 
Rat ǂ ǂ ǃ 
Pig Not detected in granule 
extracts 
Not determined ǃ 
Cow ǃ none ǃ 
Chicken ǃ Not determined ǃ 
Table 2. Diverse patterns of defensins expression in vertebrates 
In human, ǂ-defensins are expressed primarily in neutrophils, NK cells, certain T cell 
subsets, and in Paneth cells of the small intestine, where they may regulate and maintain 
microbial balance in the intestinal lumen. Moreover, low levels of ǂ-defensins expression 
have been observed in epithelial cells of digestive tract, urogenital tract of mammalian and 
the kidney of rabbit. Human ǂ-defensin-1, -2, -3, and -4, also known as neutrophil 
polypeptide (HNP), are located primarily in neutrophils, while human ǂ-defensin-5 and -6 
(HD-5, HD-6) are secreted by the small intestinal Paneth cells. Mature ǂ-defensins consist of 
29-36 amino acids including six conserved cysteine residues. 
ǃ-defensins are the most widely distributed, being secreted by leukocytes and epithelial cells 
of many kinds. For example, they can be found on the tongue, skin, cornea, salivary glands, 
kidneys, esophagus, and respiratory tract. It has been suggested that some of the pathology 
of cystic fibrosis arises from the inhibition of ǃ-defensins activity on the epithelial surfaces of 
the lungs and trachea due to higher salt content. ǃ-defensins were first found from tracheal 
epithelium cells of cattle and in granulocytes of cattle (Diamond et al., 1991). The first 
human β-defensin (HBD-1) was discovered in 1995, which is mainly expressed in kidney, 
urogenital tract and other epithelial cells (Bensch et al., 1995). In 1997 Harder et al. first isolated 
and purified HBD-2 from the skin of psoriasis patients (Harder et al., 1997), and it is mainly 
expressed in damaged skin, oral mucosa and epithelium of infected lungs. HBD-3 is observed 
to be mainly expressed in human keratinocytes and airway epithelial cells. HBD-4 is mainly 
expressed in testis, uterus, neutrophils, thyroid, lung and kidney. In addition, HBD-5 and 
HBD-6 are only present in testicular cells (Harder et al., 2001; Garcia et al., 2001). ǃ-defensins 
are composed of 36-42 amino acid residues, containing 6 conserved cysteine residues. 
θ-defensins are rare and thus far have been found only in the leukocytes of the rhesus 
macaque (Tran et al., 2008), and the olive baboon, Papio anubis, being vestigial in humans 
and other primates (Angie & Michael 2008; Garcia et al., 2008). Interestingly, θ-defensins are 
negative in humans and New World monkeys (Garcia et al., 2008; Nguyen et al., 2003). θ-
defensins are macrocyclic octadecapeptides expressed only in old world monkeys and 
orangutans, and produced by the pair-wise, head-to-tail splicing of nonapeptides derived 
from their respective precursors. Rhesus θ-defensin-1 (RTD-1) is a unique cyclic 
antimicrobial peptide first identified in rhesus macaque leukocytes (Tang et al., 1999), and 
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produced by a novel post-translational processing pathway involving the excision of two 9-
amino-acid oligopeptides from a pair of propeptides that is further stabilized by three 
disulfide bonds. θ-defensins possess broad antimicrobial properties in vitro against bacteria, 
fungi, and viruses (Owen et al., 2004; Tran et al., 2008; Wang et al., 2004). Nevertheless, they 
exhibit very low levels of toxicity in vitro (Tran et al., 2008) and in vivo, indicating that they 
may have utilities as therapeutic agents. 
4. Biosynthesis of defensins 
4.1 Regulation of α-defensins biosynthesis 
ǂ-defensins genes map to 8p21–8pter through 8p23 in human and are syntenic in mice 
(Ouellette, 2006; Ouellette et al., 1989b; Patil et al., 2004; Sparkes et al., 1989), which are 
expressed predominantly in myeloid cells or in Paneth cells (Selsted & Ouellette, 1995). 
4.1.1 Transcriptional regulation 
Myeloid ǂ-defensins mRNA are expressed almost exclusively in the bone marrow, where 
they are found at the highest levels in promyelocytes and at lower levels in myeloblasts and 
myelocytes (Yount et al., 1995). Enteric ǂ-defensins occur exclusively in Paneth cells in 
normal small bowel (Cunliffe et al., 2001; Ouellette et al., 1999; Ouellette et al., 2000; Porter 
et al., 1997b; Selsted et al., 1992 ). Myeloid and Paneth cell ǂ-defensins genes differ in that 
genes expressed in cells of myeloid origin consist of three exons, whereas those expressed in 
Paneth cells have only two exons (Bevins et al., 1996; Huttner et al., 1994; Jones & Bevins, 
1992; Jones & Bevins, 1993; Lala et al., 2003). In Paneth cell ǂ-defensins genes, the 5’-
untranslated region and the preprosegment are coded by exon 1, but an additional intron 
interrupts the 5’-untranslated region of myeloid ǂ-defensins gene transcripts (Ouellette & 
Selsted, 1996). 
The differentiation of Paneth cells is determined by continuous Wnt signaling via the 
frizzled-5 receptor, and transcription of ǂ-defensins genes in Paneth cell is mediated by ǃ-
catenin/TCF-4 recognition sites in the 5’-upstream regions of the gene transcription start 
sites as well as upstream of the gene coding for matrix metalloproteinase-7 (MMP-7), the 
mouse ǂ-defensins convertase (Andreu et al., 2005; He et al., 2004; Pinto & Clevers, 2005; 
Van et al., 2005). Monocytes and NK cells also contain ǂ-defensins mRNAs and peptides, 
but regulatory elements equivalent to ǃ-catenin/TCF-4 sites in Paneth cell ǂ-defensins genes 
remain to be found in myeloid ǂ-defensins gene promoters. 
4.1.2 Posttranslational activation of α-defensins 
Both ǂ- and ǃ-defensins are initially synthesized as preprodefensins, consisting of a 
characteristic amino terminal signal sequence, a propiece, and the mature peptide at the 
carboxy terminal end of the prepropeptide. The processing and release of ǂ-defensins seem 
to be peptide- and host species-specific. α-defensins have been isolated from primate 
leukocytes and neutrophils of several rodents including rats, rabbits, guinea pigs, and 
hamsters. Myeloid ǂ-defensins RNAs are expressed almost exclusively in the bone marrow, 
where they occur at the highest levels in promyelocytes and at lower levels in myeloblasts 
and myelocytes. Although neutrophils contain high levels of ǂ-defensins peptides, defensins 
mRNAs are degraded during neutrophil differentiation. In contrast, circulating monocytes 
contain both ǂ-defensins mRNAs and peptides. The proteolytic pathway required to 
produce mature HNPs from their proforms is active only in myeloid cells (Valore & Ganz, 
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1992). Newly synthesized proHNPs are processed to mature defensins and then the mature 
peptides are stored in cytoplasmic granules. The propiece of proHNPs is important for the 
normal cellular trafficking during defensins biosynthesis and functions as an intramolecular 
inhibitor of defensins cytotoxicity (Liu & Ganz, et al., 1995; Valore et al., 1996). 
Unlike human neutrophil defensins, Paneth cell defensins HD-5 and HD-6 are stored as 
precursor in the secretory granules of Paneth cells (Ghosh et al., 2002). The biosynthesis of 
Paneth cell pro-ǂ-defensins involves post-translational proteolytic activation. Although the 
enzymes that mediate pro-ǂ-defensins processing in myeloid and epithelial cells are likely 
to differ, the overall processing schemes are similar in that all are processed from precursor 
by specific proteolytic cleavage steps. 
Evidences have been shown that ǂ-defensins are present in murine Paneth cells under germ-
free conditions (Salzman et al., 2007; Ouellette & Lualdi, 1990; Putsep et al., 2000), and in 
human Paneth cells prenatally (Mallow et al., 1996). These findings indicate that ǂ-defensins 
expression is independent on bacterial stimulation. In contrast, expression of Reg3Ǆ and 
angiogenin in Paneth cells is closely associated with the presence of microbes in the 
intestinal lumen. 
Transcription levels of ǂ-defensins in Paneth cells are directed, in part, through factors 
intimately linked to cellular differentiation (Batlle et al., 2002). Clevers and colleagues have 
shown that Tcf7-L2 (also known as Tcf-4) is a key transcription factor for ǂ-defensins 
expression in Paneth cells. Activity of this transcription factor is linked to Wnt/ǃ-Catenin 
signaling gradients in the crypt and appears to represent a master regulator for Paneth cell 
differentiation (Van et al., 2005). Defensins expression is found to be low in human neonates 
(Mallow et al., 1996), unweaned mice (Ouellette & Cordell, 1988; Ouellette et al., 1989a) and 
rats, but increases dramatically with maturation. Aside from this developmental pattern, ǂ-
defensin expression is relatively constitutive under most conditions. However, levels vary 
significantly in association with some disease states (Kelly et al., 2004; Wehkamp et al., 2004, 
2005). 
Additional regulatory mechanisms of ǂ-defensins activity are granule secretion and 
proteolytic processing of precursor peptides (Bevins, 2004). Paneth cells secrete their dense 
secretory granules into the crypt lumen in response to bacterial products (including 
muramyl dipeptide, a component of bacterial peptidoglycan), but not to fungal or protozoal 
stimuli (Qu et al., 1996; Ayabe et al., 2000). These findings suggest that in vivo control of ǂ-
defensins secretion in Paneth cells may be linked to microbial sensors. Interestingly, recent 
studies have identified that Paneth cells could express nucleotide oligomerization domain 
(NOD)2 (a critical intracellular pattern recognition receptor for muramyl dipeptide), whose 
precise functions in Paneth cells are yet to be clearly determined (Lala et al., 2003; Rumio et 
al., 2004; Kobayashi et al., 2005). Cholinergic agonists can also stimulate ǂ-defensins 
secretion by a mechanism that appears to involve both increased cytosolic Ca2+ and mIKCa1 
potassium channels (Satoh et al., 1995; Ayabe et al., 2002). 
Proteolytic processing is an important step in regulating expression of active Paneth cell-
derived defensins. Paneth cell-derived ǂ-defensins, like myeloid-derived ǂ-defensins, are 
initially expressed as amino acid prepropeptides. After removal of the N-terminal signal 
sequence, the Paneth cell-derived ǂ-defensins propeptides require processing by an 
endopeptidase to produce a mature active peptide. However, there are differences in this 
general theme when comparing with rodents and primates. MMP-7 (also known as 
matrilysin), an endoprotease expressed in mouse Paneth cells, is essential for processing of 
the ǂ-defensins propeptide to active mature peptides in mice (Wilson et al., 1999; Ouellette, 
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2005; Selsted & Ouellette, 2005). MMP-7 processes the ǂ-defensins propeptides to their 
active mature peptide counterparts at precisely the same cleavage site in vitro as identified in 
vivo (Selsted et al., 1992; Shirafuji et al., 2003). Polymorphic isoforms of ǂ-defensins 
containing mutations at MMP-7 cleavage site exist in some mouse strains, which influence 
post-translational processing and yield differences in mature peptides. Characterization of 
Paneth cell-derived ǂ-defensins suggests that MMP-7 is also the endoprotease responsible 
for processing in rats (Qu et al., 1996). In rhesus macaques, characterization of Paneth cell-
derived ǂ-defensins indicates that trypsin is likely the endoprotease responsible for 
processing in these primates as well (Tanabe et al., 2004a, 2004b). In contrast, MMP-7 is not 
detected in human Paneth cells, and trypsin is the endoprotease expressed in Paneth cells, 
which is responsible for processing of ǂ-defensins propeptides (Ghosh et al., 2002). 
In humans Paneth cell-derived ǂ-defensins are stored in secretory granules as propeptides 
(Ghosh et al., 2002; Cunliffe, et al., 2001). The propeptide trypsinogen is also stored in these 
same Paneth cell granules. Current hypotheses point that trypsinogen is activated to trypsin 
after secretion, which then converts proHD5 into mature HD5 in either the crypt or 
intestinal lumen. In contrast, some of the ǂ-defensins pool in mouse Paneth cells is 
processed intracellularly and stored as mature MMP-7-cleaved peptides (Ouellette, 2005; 
Selsted & Ouellette, 2005). Since proteolytic processing is central to the biology of Paneth 
cell ǂ-defensins, it will be interesting to determine how and why rodents and primates 
diverged in their mechanisms for achieving this important post-translational modification. 
Evidence for the key role of Paneth cell ǂ-defensins in host defense against orally ingested 
pathogens comes from murine models. Targeted disruption of the MMP-7 gene, which 
encodes the processing endoprotease of murine Paneth cell ǂ-defensins precursors, has 
shown to impair the ability of mice to produce active cryptdin. Compared to their wild-type 
littermates, the MMP-7 null mice cannot effectively clear orally administered noninvasive 
Escherichia coli, and they succumb more rapidly to lower doses of virulent Salmonella 
enterica serovar Typhimurium. However, MMP-7 may have other biological functions that 
could have altered the susceptibility to these bacterial challenges. Therefore, Salzman et al. 
utilized a complementary approach to analyze Paneth cell ǂ-defensins function (Salzman et 
al., 2003). Mice were genetically engineered to express the human Paneth cell ǂ-defensins 
HD5. Under transcriptional control of HD5’s own endogenous promoter, these transgenic 
mice expressed HD5 in Paneth cells. Expression levels of the transgene were similar to those 
of the endogenous ǂ-defensins (cryptdins), pointing that this murine model can assess the 
biological effects of physiologically relevant levels of HD5. The transgenic mice were more 
resistant to orally administered Salmonella. Thus, these two models point to a central role 
for Paneth cell ǂ-defensins in innate immunity of the small intestine against orally ingested 
pathogens. 
4.2 Regulation of β-defensins biosynthesis 
It is likely that ǃ-defensins gene products are produced and stored as mature peptides 
because pro-ǃ-defensins have not been recovered from natural producing cells and insect 
cells, in which transfected with ǃ-defensins cDNA always release bioactive mature ǃ-
defensins (Aono et al., 2006; Shi, 2007). HBD-1 is constitutively expressed in the epithelial 
cells in the small intestine and colon and its expression is not influenced by inflammation or 
bacterial infection. Despite normally absent, HBD-2 and HBD-3 can be induced in normal 
colon epithelial cells (O'Neil et al., 1999; Fahlgren et al., 2004). Induction of HBD-2 is an NF-
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κB-dependent process in the intestinal epithelium because blocking NF-κB activation could 
inhibit the upregulation of HBD-2 in response to IL-1 stimulation or bacterial infection 
(O'Neil et al., 1999; Voss et al., 2006). Unlike professional phagocytes and Paneth cells, 
epithelial cells expressing ǃ-defensins do not have visible granules. How ǃ-defensins are 
stored and released from intestinal epithelial cells remains obscure. 
4.3 Regulation of θ-defensins biosynthesis 
Rhesus θ-defensins peptides assemble from two distinct precursor molecules with each 
hemi-precursor contributing a nine-amino acid moiety to the final RTD-1 peptide, although 
the molecular mechanisms that catalyze or facilitate θ-defensins assembly in primates are 
not understood (Tang et al., 1999). Rhesus pro-RTDs are products of different genes that 
resemble the three-exon myeloid ǂ-defensins genes, except that they are truncated by stop 
codons in exon 3. In addition to heterodimeric RTD-1, homodimeric θ-defensins RTD-2 and -
3 have also been isolated from monkey neutrophils (Tran et al., 2002; Leonova et al., 2001). 
ǂ-defensins gene mutations that give rise to the θ-defensins genes (DEFT) apparently arise 
in Old World monkeys, because rhesus DEFT homologs have not been found in prosimians 
or in New World monkeys (Lehrer, 2004). Humans, chimpanzees, and gorillas lack θ-
defensins, because the DEFT genes of those species harbor mutations that create premature 
stop codons in the prepro regions of the precursors. However, at least one mutant human 
DEFT gene still is actively transcribed, and its nonfunctional mRNA accumulates to high 
abundance at several sites of expression (Cole et al., 2002). 
5. Role of defensins in immune response 
In the gastrointestinal tract, these peptides have bactericidal activity by forming micropores 
in the phospholipid bilayer of bacterial membranes, causing loss of structural integrity and 
collapse of the bacterial cells. This antimicrobial quality allows defensins to protect the host 
epithelium and stem cells from virulent pathogens and also help to regulate the number and 
composition of commensal microbiota (Ramasundara et al., 2009). 
5.1 Defensins in innate immunity 
The innate immunity is the most primitive defense system against pathogens, which has not 
only the generalized mechanical barriers and antibacterial action, but also includes 
functional defense barrier built by phagocytosis and inflammatory response. 
5.1.1 Antibacterial activity 
Defensins have a broad antibacterial spectrum, which can effectively kill Gram-negative and 
-positive bacteria, fungi, spirochetes, and some parasites. Importantly, ǂ-defensins have 
stronger activity against Gram-positive bacteria, while the ǃ-defensins have stronger activity 
against Gram-negative and -positive bacteria. HBD-3 has stronger bactericidal activity 
against Staphylococcus aureus, Streptococcus pyogenes, Pseudomonas aeruginosa, Escherichia coli 
and Actinomycetes in vitro (Maisetta et al., 2005). 
The ǂ- and ǃ-defensins expressed in the alimentary tract of human and mice have activity 
profiles and expression patterns that overlap with other mammalian peptides (Table 3). 
Intestinal ǂ-defensins have microbicidal activities against many Gram-positive (L. 
monocytogenes, S. aureus) and Gram-negative bacteria (E. coli, S. typhimurium). Similarly, HD5 
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is active against many bacterial species and the fungus C. albicans (Porter et al., 1997a; Ghosh 
et al., 2002; Ericksen et al., 2005). Surprisingly, initial reports indicate that HD6 has very 
poor antibacterial activity in vitro, despite similar ionic charge properties as HD5 (Ericksen 
et al., 2005). The most abundant ǃ-defensins, expressed chiefly in the stomach and colon, 
also have bactericidal activity in vitro. HBD-2 is microbicidal against P. aeruginosa, E. coli and 
C. albicans, but less activity against Gram-positive S. aureus (Harder et al., 1997). In contrast, 
the more cationic HBD-3 has activity against S. aureus (Harder et al., 2001) and is less 
sensitive to the ionic composition of the assay medium. HBD-1 has antibacterial activity 
(Valore et al., 1998), but it is not potent in vitro like HD6. 
 
Defensins Mr (kDa) Tissue distribution Stimuli 
HNP 1-4 3.5-4.5 Sparse lamina propria 
neutrophils in active 
inflammation seen in scattered 
intestinal epithelial cells 
Increased in active 
inflammation but possibly 
a result of increased 
neutrophilic influx 
HD-5, HD-6 3.5-4.5 Paneth cells and some villous 
epithelial cells in normal 
duodenum, jejunum and ileum 
Paneth cell metaplasia 
Constitutively expressed, 
however processing is 
required for biological 
activity 
HBD-1 3.5-4.5 Colonic epithelia (and some 
other mucosal epithelia) 
Constitutively expressed 
HBD-2, -3, -4 3.5-4.5 Colonic epithelia (and some 
other mucosal epithelia) 
Colonic plasma cells 
IL-1ǂ and entero-invasive 
bacteria 
Cryp-4 5.1 Paneth cells Uncertain 
Table 3. Defensins in the gut of human and mouse 
5.1.2 Chemotactic activity 
Various defensins have been reported to have chemotactic activity for monocytes, T cells 
and dendritic cells. In the case of HBD-1 and HBD-2, which attract memory T cells and 
immature dendritic cells, the chemoattractant activity might be due to defensins binding to 
the chemokine receptor CCR6. Although the physiological importance of this interaction has 
not yet been shown, the high concentrations of HBD-2 in inflamed skin make it probable 
that this defensins could compete effectively with the natural CCL20, despite the higher 
affinity of the latter for the CCR6. Recent structural analysis of CCL20 has indicated marked 
similarities to HBD-2 in the putative receptor binding region of CCL20. The role of this 
region in the chemotactic activity of HBD-2 needs to be confirmed by mutating the amino-
acid residues that are suspected to be involved in its interaction with CCR6. Human 
neutrophil defensins HNP1-3 have been reported to be chemotactic for monocytes, naive T 
cells and immature dendritic cells (Territo et al., 1989; Chertov et al., 1996; Yang et al., 1999; 
2000), but a specific receptor has not yet been identified. Mouse ǃ-defensin-2 acted as a 
peptide adjuvant when it was linked to a non-immunogenic tumour antigen (Biragyn et al., 
2002). This immunostimulatory activity was shown to depend on TLR-4 and its ability to 
induce dendritic-cell maturation. It is not yet certain how this receptor can bind with 
mouse ǃ-defensin-2 as well as the many other ligands attributed to it, or whether some of 
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these molecules function as efficient carriers for lipopolysaccharide, the main ligand of 
TLR-4. 
5.1.3 Paneth cell defensins regulate innate immune responses by NOD2 or TLRs 
TLRs which are the major pattern recognition receptors of innate immunity, by recognizing 
pathogen associated molecular patterns, activating the innate immune system to produce 
proinflammatory cytokines and defensins resist damage caused by pathogens (Elphick & 
Mahida, 2005). NOD2 is a new pattern recognition molecule, participating in the anti-
bacterial and anti-invasion effect of host cell by the identification of intracellular bacterial 
components. The absence of NOD2 leads to the disorder of NF-κB, resulting in imbalance of 
cytokine production and defensins secretion disorders. Kobayashi et al. found that the levels 
of two cryptdins expression were significantly reduced when NOD2 gene mutated in mice 
(Kobayashi et al., 2005). NOD2 mutations have impact on Paneth cell ǂ-defensins 
expression, whereas ǂ-defensins are the main effector molecule which Paneth cells play a 
major role in innate immunity. Therefore, intestinal epithelium could regulate the 
expression of defensins secretion to activate and regulate innate immune responses by NOD 
or TLRs through pattern recognition receptors. 
5.1.4 Blocking ACTH activity 
Evidences have demonstrated that some defensins have a role in inhibiting the effects of 
adrenocorticotropic hormone (ACTH) by binding to ACTH receptor (Zhu et al., 1987, 1989; 
Solomon et al., 1991; Tominaga et al., 1990). Although such activity could inhibit the 
production of the immunosuppressive hormone cortisol, and could therefore be useful in 
responding to infections, the physiological role of this in vitro interaction has not yet been 
shown. 
5.1.5 Other activities of defensins 
It has been reported that defensins have the ability to activate nifedipine-sensitive calcium 
channels in mammalian cells (MacLeod et al., 1991; Bateman et al., 1996). The structural 
basis of this effect is not understood. Certain mouse Paneth cell defensins could promote 
chloride secretion, probably by forming channels in the apical membrane of epithelial cells 
(Lencer, et al., 1997; Merlin et al., 2001). This activity is limited to a subset of mouse Paneth 
cell defensins, and its structural basis is not yet known. 
5.2 Defensins in acquired Immunity 
Evidences have demonstrated that ǂ- and ǃ-defensins have chemotactic activities, indicating 
that defensins are involved in attracting T cells recycling and promoting immature dendritic 
cells and monocytes homing to the site of infection. HNP-1 and HNP-2 could enhance 
severe immune deficiency (SCID) mice T cell recycling (Lillard et al., 1999). 
Intraperitoneal administration of human neutrophil peptide (HNP) significantly increased 
the production of keyhole limpet henocyanin (KLH)-specific IgG1, IgG2a and IgG2b 
antibodies 14 days after immunization. These results indicate that defensins function as 
potent immune adjuvants by inducing the production of lymphokines, which promote T 
cell-dependent cellular immunity and antigen-specific Ig production, and that defensins 
appear to act as neutrophil-derived signals that promote adaptive immune responses 
(Tani et al., 2000). 
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Increasing data have shown that ǃ-defensins participate in acquired immunization mainly 
by chemotactic induction or direct activation of antigen presenting cells, such as dendritic 
cells, to activate the T cells, resulting in enhanced specific immune response (O'Neil et al., 
1999). Previous study has confirmed that defensins contribute to host defense by disrupting 
the cytoplasmic membrane of microorganisms (Yang et al., 1999, 2000). Human ǂ-defensins 
are also chemotactic for immature dendritic cells and memory T cells. Human ǂ-defensins 
was selectively chemotactic for cells stably transfected to express human CCR6, a chemokine 
receptor preferentially expressed by immature dendritic cells and memory T cells. The ǂ-
defensin-induced chemotaxis is sensitive to pertussis toxin and inhibited by antibodies to 
CCR6. The binding of iodinated LARC, the chemokine ligand for CCR6, to CCR6-
transfected cells was competitively displaced by ǂ-defensins. Thus, ǂ-defensins may 
promote adaptive immune responses by recruiting dendritic and T cells to the site of 
microbial invasion through interaction with CCR6. In addition, defensins are also able to 
activate macrophages via TLR signaling and trigger acquired immune system. Evidence has 
shown that in cooperation with the IL-1 related protein kinase (IRAK), ǃ-defensin-2 as TLR-
4 endogenous ligand could combine with TLR4, leading to NK-κB activation and migration 
to the nucleus to activate cytokine gene transcription, upregulation of costimulatory 
molecules expression and dendritic cells maturation, thereby activate T cells, trigger a 
strong specific immune response (Biragyn et a1., 2002; Means et a1., 2000). 
6. Role of defenins in the pathogenesis of UC 
Inflammatory bowel disease (IBD) is chronic, relapsing and debilitating conditions that have 
significant impact on quality of life. IBD includes two main conditions, UC and Crohn’s 
disease (CD), which are defined based on characteristic endoscopic and histological 
findings. UC is characterised by superficial inflammation limited to the mucosa of the colon. 
In contrast, CD is characterised by discontinuous skip lesions that can occur anywhere in the 
gastro-intestinal tract with transmural inflammation and non-caseating granulomas. 
The pathogenesis of IBD is not clearly understood, and its presentation regarding disease 
localization, progression and response to therapies is unpredictable. In the intestinal tract, 
defensins contribute to host immunity and assist in maintaining the balance between 
protection from pathogens and tolerance to normal flora. However, attenuated expression of 
defensins compromises host immunity and hence may alter the balance toward 
inflammation. Altered defensins production is suggested to be an integral element in the 
pathogenesis of IBD (Table 4). 
 
Defensins Ulcerative colitis Ileal Crohn’s disease Colonic Crohn’s disease 
HNP 1-4 upregulate (infection) Unknown Unknown 
HD-5, HD-6 Upregulate, Paneth cell 
metaplasia 
Downregulate, especially 
NOD2 mutation paitent 
Upregulate, Paneth cell 
metaplasia 
HBD-1 Downregulate Downregulate Downregulate 
HBD-2, -3 Upregulate (infection) No obvious change No obvious change 
HBD-4 Upregulate No obvious change No obvious change 
Cryp-2 Upregulate Unknown Unknown 
Cryp-4 Unknown Unknown Downregulate 
Table 4. Defensins expression in ulcerative colitis, and colonic and ileal Crohn’s disease 
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6.1 α-defensins in UC 
6.1.1 Paneth cell-derived α-defensins in UC 
ǂ-defensins are highly expressed by Paneth cells (Fig. 1). These cells are located at the 
base of the crypts of Lieberkühn and are distributed from the duodenum to the ileum. 
Their location in the crypts suggests an essential role of protecting the epithelial stem 
cells, located in close proximity. Paneth cells are filled with large apically located granules 
(Fig. 1A) and have ultrastructural hallmarks (an extensive endoplasmic reticulum  
and well-developed Golgi) of prototypical secretory cells. The development of small 
intestine gland is imperfect in newborn BALB/c mice, and no Paneth cells were seen 4 
days before. However, Paneth cells could be detected in small intestine gland 6 days after 
birth (Fig. 1C). In addition to ǂ-defensins, human Paneth cells also secrete lysozyme, Reg 
3Ǆ, and phospholipase A2 (Ouellette & Bevins, 2001). Of these antimicrobials, the ǂ-
defensins are the most abundant. In addition, mouse Paneth cells also express numerous 
cryptdin-related peptides (Fig. 1B) and angiogenin (Ouellette & Bevins, 2001; Hornef et 
al., 2004). 
Numerous data have proven that intestinal luminal microbes play an important role in 
the pathogenesis of IBD (Janowitz et al., 1998; Sartor, 2001; Marteau et al., 2004; Strober et 
al., 2007). NOD2, the aforementioned intracellular peptidoglycan receptor for muramyl 
dipeptide is the first susceptibility gene identified for IBD (Hugot et al., 2001; Ogura et al., 
2001). Mutations in NOD2 are likely responsible for the genetic predisposition to disease 
in approximate one third of patients with CD, especially for ileal disease (Bonen & Cho, 
2003; Hugot 2004). NOD2 is expressed in macrophages and Paneth cells. Since Paneth cell 
antimicrobials may affect the microbial composition of the small intestine, deleterious 
changes in the bacterial microbiota that result from altered Paneth cell function  
might contribute to the pathogenesis of IBD (Ouellette & Bevins, 2001; Fellermann et al., 
2003). 
Wehkamp et al. have reported that low levels of Paneth cell ǂ-defensins mRNA and protein 
are present in inflamed ileum of CD patients as compared to non-IBD controls (Wehkamp et 
al., 2004, 2005). Interestingly, the specific decrease in ǂ-defensins is more pronounced in CD 
patients with NOD2 gene mutation. Consistent with this, Kobayashi et al. reported a 
decrease expression of Paneth cell ǂ-defensins (cryptdin) and cryptdin related sequences in 
NOD2-knockout mice (Kobayashi et al., 2005). As compared to wild-type controls, the 
NOD2-knockout mice are more susceptible to gastric, but not systemic, challenges with the 
Gram-positive bacterium Listeria monocytogenes. The decreased expression of Paneth cell 
antimicrobials in the NOD2-knockout mice is proposed to underlie the increased 
susceptibility. 
6.1.2 α-defensins by colonic Paneth cells 
Evidences have shown that HD-5 and HD-6 are not present in normal colonic mucosa. 
However, Cunliffe et al. detected HD5 in the colonic crypt region of IBD samples (Cunliffe 
et al., 2001). The appearance of these defensins is due to the phenomenon of Paneth cell 
metaplasia during colonic inflammation. HD-5 mRNA expression is enhanced in both 
idiopathic and nonidiopathic inflammatory states of the large bowel, whereas HD-6 is 
specifically related to CD and UC. Immunohistochemical staining has confirmed that the 
presence of HD-5 in colonic epithelium may be of importance in maintaining the mucosal 
barrier and controlling microbial invasion in IBD (Yamaguchi et al., 2009). 
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Fig. 1. Paneth cell granules contain ǂ-defensins 
A: Hematoxylin-eosin stain of small intestinal crypt shows Paneth cell granules (Bright Red) 
containing ǂ-defensins in ileum of BALB/c mice. Abundant large secretory vesicles of 
D E 
C 
B A 
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Paneth cells are adjacent to the crypt lumen. Scale bar = 20 μm. 
B: Immunohistochemical staining demonstrates Cryptdins-4 in the granules of Paneth cell in 
the ileum crypts of BALB/c mice. Scale bar = 10 μm. 
C: The Paneth cells in intestine of newborn BALB/c mice. The development of small 
intestine gland is imperfect in newborn BALB/c mice, and no Paneth cells were seen 4 days 
before. However, Paneth cells could be detected in small intestine gland 6 days after birth. 
a: duodenum, 4 days; b: jejunum, 4 days; c: ileum, 4 days; d: duodenum,10 days; e: jejunum, 
10 days; f: ileum, 10 days. Scale bar = 20 μm 
D: Real-time PCR analysis of mRNA encoding Paneth cell ǂ-defensins (HD-5 and HD-6) 
antimicrobial peptides in human ileum. 
E: Immunogold electron microscopy localizes HD5 to Paneth cell secretory granules. 
Transmission electron micrograph of human ileum crypt with immunogold staining for 
HD5. Defensin-rich granules were found exclusively in Paneth cells 
6.1.3 Other α-defensins in the gut 
Human HNP-1, -2, -3, and -4 have been found to be present in the granules of 
polymorphonuclear cells and intestinal epithelial cells, where they participate in systemic 
innate immunity (Cunliffe, 2003). Cunliffe and colleagues have observed that the mRNA 
levels of HNP-1, -2, and -3 are significantly increased in inflamed mucosa of IBD patients 
compared with controls (Cunliffe, 2003), indicating that a-defensins are also involved in the 
pathogenesis of IBD. 
Evidences have shown that expression of HNP-1, -2 and -3 mRNA is highly increased in 
inflamed colon of UC patients than in healthy controls. Further research also proved that the 
expression levels of HNP1-3 mRNA, NO and MDA is significantly higher in colonic mucosa 
of UC patients than in that of normal controls. The expression of HNP-1, -2, and -3 mRNA is 
correlated with the levels of NO and MDA in the inflamed mucosa in UC patients, the 
induction of HNP-1, -2, and -3 is involved in the process of inflammation and damage of 
UC. HNP-1, -2, and -3, NO and MDA might have synergistic effects on colonic inflammation 
(Cunliffe et al., 2002, 2003). These HNPs are also significantly increased in sera of IBD 
patients compared with controls, and being significantly correlated with CD activity index, 
peripheral white blood cell counts, serum CRP values and TNF-ǂ levels (Yamaguchi et al., 
2009). 
6.2 β-defensins in UC 
6.2.1 Inducible β-defensins in UC 
Evidences have shown that expression of the inducible ǃ-defensins is significantly increased 
in inflamed mucosal of UC patients compared with controls. Moreover, HBD-2 expression 
has also been found to be significantly increased in inflamed colon of UC patients compared 
with that in controls and CD patients (Wehkamp et al., 2002). In mucosal biopsies, HBD-1 
expression is marginally decreased in both CD and UC patients, while HBD-2 is increased 
exclusively in UC but not in CD. Interestingly, expression of HBD-3 is found to be strongly 
correlated with HBD-2 in UC (Wehkamp et al., 2003). 
6.2.2 Colonic β-defensins 
It has been reported that epithelial cells and plasma cells in the lamina propria of colon 
express HBD. Importantly, expression of HBD-1 is constitutively, while expression of HBD-
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2, -3, and -4 is induced by various inflammatory and bacterial stimuli. The pathway 
responsible for induction of HBD is not completely understood, however it has been 
presumed that NOD2 signaling is involving in triggering transcription expression of HBD 
genes (Voss et al., 2006). Colonic plasma cells also express HBD-2, -3 and -4, but it is unclear 
whether this expression is constitutive or inducible (Rahman et al., 2007). 
Previous studies have found that colonic mucosa HBD-1 expression is decreased in UC, and 
this reduction may result in the decrease of antibacterial activity of mucosal immune 
system, leading to bacterial invasion secondary inflammatory response. Further studies 
suggest that defensins deficiency is due to mucosal surface destruction as a result of 
inflammatory changes, indicating that reduced defensins expression is a symptom of the 
disease and not the cause (Ramasundara et al., 2009). 
Relative low level of HBD-2 expression is found in epithelial cells of normal colon, but 
significantly increased in inflamed colon (O’Neil et al., 1999). In feces from healthy control 
individuals, low levels of HBD-2 were detectable, which are also markedly increased under 
inflammatory conditions (Kapel et al., 2009). In a study by Wehkamp and associates, HBD-2 
mRNA was detectable in only 18% of control biopsies compared to 34% in CD and 53% in 
UC (Wehkamp et al., 2002). In addition, there was increased HBD-2 expression in inflamed 
compared to non-inflamed areas of CD patients and similarly in UC (Wehkamp et al., 2003). 
O’Neil and colleagues also demonstrated that HBD-2 mRNA was expressed by colonic 
epithelial cells in response to stimulation by proinflammatory mediators IL-1ǂ and entero-
invasive bacteria (O’Neil et al, 1999; Fahlgren et al, 2003). In addition, HBD-3 and HBD-4 are 
expressed minimally in normal intestinal epithelium, and that there was no difference in 
expression for patients with colonic CD. In contrast, there was a significant increase of HBD-
3 and HBD-4 in UC (Fellermann et al., 2006; 2007). 
Overall, HBD-1 is constitutively expressed in normal intestinal epithelial cells and play 
foundational defense roles in the mucosal immune, while HBD-2, -3 and -4 could be 
inducted to express in inflamed mucosa of UC patients and play a defense role in 
inflammation response. 
7. Defensins therapy in UC 
Imbalance of intestinal mucosal immunity is an important condition for the pathogenesis of 
UC, and the defensins is an important factor to maintain the immune response in intestinal 
mucosa. Defensins play an important role in the prevention and treatment of mucosal 
inflammation. Consistent with this, evidences have proven that defensins could inhibit the 
development of neonatal colitis in mice caused by Escherichia coli (Sherman et al., 2005). 
Moreover, defensins also have certain effects on the inhibition of bacterial translocation and 
control of intestinal infection, which may substitute for antibiotics in the prevention of 
bacterial infection and some inflammatory diseases. Therefore, monitoring of defensins will 
help us to evaluate the severity of inflammation (Hiratsuka et al., 1998). A new approach 
using defensins therapy may shed some light on management of infectious and 
inflammatory conditions such as UC. HBD-1-expressing Escherichia coli clone has been 
generated, and defensins protein with biological activity is purified (Cipakova et al., 2004, 
2005). HBD-2 gene was also cloned from the lesions of human condyloma acuminatum, 
and an expression vector was constructed and transformed into Escherichia coli (Fang et 
al., 2002). These approaches may allow us to have a clinical trial in the treatment of UC in 
the future. 
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8. Outlook 
Since innate immune responses in the gut are directed against luminal bacteria, a defect in 
the expression and/or function of defensins could give rise to an increase in frequency and 
severity of intestinal infections. Such a deficiency could lead to gradual bacterial invasion, 
inflammation and a loss of tolerance to gut bacteria. Although this presumes that a 
defensins deficiency is a primary event in the pathogenesis of IBD, it also possible that the 
deficiency is a secondary event, occurring as a consequence of the disease. The pathogenesis 
of UC is not clear, but increasing data have suggested that the abnormalities of intestinal 
mucosal immune system play a decisive role in the occurrence and development, while the 
intestinal defenses play an important role in maintaining the balance of mucosal immune. 
Defensins function as the effective and regulatory molecules of the immune system in the 
gut. Further study on relationship between defenses and UC will be conducive to 
understand the pathogenesis of UC, but also provide new approaches for the treatment. 
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